Passage Bio, Inc. — Form 8-K Summary
Business context and reporting period
Passage Bio, Inc., a biotechnology company listed on Nasdaq under the symbol PASG, filed a Form 8-K reporting executive compensation actions. The report concerns discretionary cash compensation for services rendered during the fiscal year ended December 31, 2020. The earliest reported event was February 10, 2021; the filing was signed February 17, 2021.
Compensation and other key financial information
| Executive | Role | Discretionary payment | Recalculated 2020 total compensation |
|---|---|---|---|
| Bruce Goldsmith, M.D. | Chief Executive Officer and President | $258,750 | $16,695,536 |
| Jill M. Quigley | Chief Operating Officer | $202,950 | $4,349,830 |
| Gary Romano, M.D. | Chief Medical Officer | $191,500 | $2,180,109 |
Total discretionary payments were $653,200. The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, operating guidance, or other financial metrics.
Material changes versus the prior comparable disclosure
The payments were approved by the Board upon recommendation of the Compensation Committee based on the Company’s and executives’ achievement of fiscal 2020 performance objectives. The payments were not included in the executive compensation table in the Company’s January 19, 2021 Form S-1 because the amounts had not yet been determined or were not calculable.
- Dr. Goldsmith’s reported compensation increased from $16,436,786 to $16,695,536, an increase of $258,750.
- Ms. Quigley’s reported compensation increased from $4,146,880 to $4,349,830, an increase of $202,950.
- Dr. Romano’s reported compensation increased from $1,988,609 to $2,180,109, an increase of $191,500.
Guidance, outlook, risks, contingencies, and unusual items
The filing contains no operating or financial guidance and does not describe new risks, contingencies, litigation, or other unusual items. The principal disclosed item is the retroactive determination and payment of fiscal 2020 non-equity incentive compensation.
Key facts for investors to verify
- Confirm the final payment amounts and their treatment in the Company’s subsequent audited financial statements and proxy disclosure.
- Assess the effect of the $653,200 aggregate payments on fiscal 2020 compensation expense and net loss.
- Review the performance objectives and Compensation Committee rationale in related proxy or annual-report disclosures.
- Verify whether any additional 2020 incentive compensation or related-party compensation adjustments were disclosed elsewhere.